Clinical Trial

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification. This study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-15.
Trial Details
NCT Number NCT07593170
Lead Sponsor Central South University
Collaborators: Hunan Children's Hospital
Conditions Obesity, Obese Adolescents, Obese Children and Adolescents, Akkermansia Muciniphila
Enrollment 100 participants
Start Date 2026-06-06
Primary Completion 2026-12-20 (estimated)
Study Completion 2027-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-03